Obesity treatment faces challenges in access and awareness: report

The disease’s prevalence is expected to grow 0.7% annually across seven major markets.

Despite notable advancements in obesity treatment, challenges such as limited access to care remain, according to GlobalData.

An increased awareness of what this condition entails and what other diseases it can lead to remains crucial, said Costanza Alciati, Pharma Analyst at GlobalData.

The disease’s prevalence is expected to grow 0.7% annually across the seven major markets through 2031.

“By 2031, GlobalData expects 23 candidates to be approved in the major markets. This will offer a wider range of options for patients, hoping that treatment access will have improved by then,” Alciati said.

Access to specialists and affordable treatments also remains a barrier to the landscape, the analyst added.

7MM = US, France, Germany, Italy, Spain, the UK, and Japan.